Clinical Significance of Minimal Residual Disease in Childhood Acute Myeloid Leukemia

International Journal of Hematology

Volumn 79, Issue 3, 2004, Pages 243-249

  Miyamura, Takako ^a   Sakata, Naoki ^a   Okamura, Takayuki ^a   Yasui, Masahiro ^a   Inoue, Masami ^a   Yagi, Keiko ^a   Sako, Masahiro ^b   Komada, Yoshihiro ^c   Matsuyama, Takaharu ^d   Oda, Megumi ^e   Park, Yong Dong ^f   Kawa, Keisei ^a  

^a RESEARCH INSTITUTE FOR MATERNAL AND CHILD HEALTH   (Japan)

^b OSAKA CITY GENERAL HOSPITAL   (Japan)

^c MIE UNIVERSITY   (Japan)

^d JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

^e OKAYAMA UNIVERSITY   (Japan)

^f NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

AML; Childhood; MRD; Stem cell transplantation; WT1

Indexed keywords

CYTARABINE; ETOPOSIDE; IDARUBICIN; MITOXANTRONE;

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; AML1 MTG8 GENE; ARTICLE; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE MARKER; DRUG RESPONSE; EVALUATION; FEMALE; FUSION GENE; GENE EXPRESSION REGULATION; GENE FUNCTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MALE; MINIMAL RESIDUAL DISEASE; MYH11 CBFBETA GENE; ONCOGENE; PML RARALPHA GENE; PREDICTION; PROGNOSIS; RISK FACTOR; TREATMENT PLANNING; WT1 GENE;

EID: 2442506981     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.03113     Document Type: Article

References (31)

1. Campana D, Pui CH. Detection of minimal residual disease in acute leukemia: methodologic advance and clinical significance. Blood. 1995;85:1416-1434.
2. Fey MF, Kulozik AE, Hansen-Haagge TE, Tobler A. The polymerase chain reaction: a new tool for detection of minimal residual disease in hematological malignancies. Eur J Cancer. 1991;27:89-94.
3. Sklar J. Polymerase chain reaction: the molecular microscope of residual disease. J Clin Oncol. 1991;9:1527-1532.
4. Morgan GJ, Hughes T, Bartam CR, et al. Polymerase chain reaction for detection of residual leukemia. Lancet. 1989;1:928-929.
5. Chang KS, Fan YH, Drabkin H, et al. Expression of AML1-ETO fusion transcripts and detection of minimal residual disease in t(8; 21)-positive acute myeloid leukemia. Oncogene. 1993;8:983-988.
6. Andrieu V, Radford-Weiss I, Macintyre E, et al. Molecular detection of t(8;21)/AML1-ETO in AML M1/M2: correlation with cytogenetics, morphology and immunophenotype. Br J Haematol. 1996;92:855-865.
7. Maruyama F, Stass SA, Chang KS, et al. Detection of AML1/ETO fusion transcript as a tool for diagnosing t(8;21) positive acute myelogenous leukemia. Leukemia. 1994;8:40-45.
8. Nucifora G, Larson RA, Rowley JD. Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission. Blood. 1993;82:712-715.
9. Scahrnhorst V, van der Eb AJ, Jochemsen AG. WT1 proteins: functions in growth and differentiation. Gene. 2001;273:141-161.
10. Inoue K, Ogawa H, Sugiyama H, et al. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood. 1997;89: 1405-1412.
11. Gessler M, Poustka A, Cavenee W, et al. Homozygous deletion in Wilms tumors of a zinc-finger gene identified by chromosome jumping. Nature. 1990;343:774-778.
12. Call KM, Glaser T, Ito CY, et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell. 1990;60:509-520.
13. Rose EA, Glaser T, Jones C, et al. Complete physical map of the WAGR region of 11p13 localizes a candidate Wilms' tumor gene. Cell. 1990;60:495-510.
14. Scahrnhorst V, van der Eb AJ, Jochemsen AG. WT1 proteins: functions in growth and differentiation. Gene 2001;273:141-161.
15. Brieger J, Weidemann E, Bergmann L, et al. The expression of the Wilms' tumor gene in acute myelocytic leukemias as a possible marker for leukemic blast cells. Leukemia. 1994;8:2138-2143.
16. Miwa H, Bearn M, Saunders GF. Expression of the Wilms' tumor gene (WT1) in human leukemia. Leukemia. 1992;6:405-409.
17. Yamagami T, Sugiyama H, Kishimoto T, et al. Growth inhibition of human leukemic cells by WT1 (Wilms' tumor gene) antisense oligodeoxy nucleosides: implications for the involvement of WT1 in leukemogenesis. Blood. 1996;87:2878-2884.
18. Gaiger A, Schmid D, Jager U, et al. Detection of WT1 transcript by RT-PCR in complete remission has no prognostic relevance in de novo acute myeloid leukemia. Leukemia. 1998;12: 1886-1894.
19. Krauter J, Petr W, Heal G, et al. Detection of karyotypic aberrations in acute myeloblastic leukemia: a prospective comparison between PCR/FISH and standard cytogenesis in 140 patients with de novo AML. Br J Hematol. 1998;103:72-78.
20. Kondo M, Kudo K, Horibe K, et al. Real-time quantitative reverse transcription-polymerase chain reaction for the detection of AML1-MTG8 fusion transcripts in t(8;21)-positive acute myelogenous leukemia. Leuk Res. 2000;24:951-956.
21. Shichishima T, Okamoto M, Maruyama Y, et al. HLA class 2 haplotype and quantitation of WT1 RNA in Japanese patients with paroxysmal nocturnal hemoglobinuria. Blood. 2002;100:22-28.
22. Novak M, Laczika K, Haas OA, et al. Novel CBFβ/MYH11 fusion transcripts and alternative splicing in acute myeloid leukemia with inversion of chromosome 16. Blood. 1995;86: 2449-2450.
23. Kusec R, Leczica K, Jaeger U, et al. AML1/ETO fusion mRNA can be detected in remission blood samples of all patients with t(8;21) acute myeloid leukemia after chemotherapy or autologous bone marrow transplantation. Leukemia. 1994;8:735-739.
24. Laczika K, Mitterbauer M, Hager U, et al. Rapid achievement of PML/RARα polymerase chain reaction (PCR) negativity by combined treatment with all trans retinoic acid and chemotherapy in acute promyelocytic leukemia: a pilot study. Leukemia. 1994;8:1-5.
25. Wells RJ, Arthur DC, Lampkin BC, et al. Prognostic variables in newly diagnosed children and adolescents with acute myeloid leukemia: Children's Cancer Group Study 213. Leukemia. 2002;16: 601-607.
26. Brieger J, Weidemann E, Maurer U, et al. The Wilms' tumor gene is frequently expressed in acute myeloblastic leukemias and may provide a marker for residual blast cells detectable by PCR. Ann Oncol. 1995;6:811-816.
27. Miwa H, Beran M, Saunders GF. Expression of Wilms' tumor gene (WT1) in human leukemias. Leukemia. 1993;7:970-977.
28. Wattjes MP, Krauter J, Heil G, et al. Comparison of nested competitive RT-PCR and real-time RT-PCR for the detection and quantification of AML1/MTG8 fusion transcripts in t(8;21) positive acute myelogenous leukemia. Leukemia. 2000;14:329-335.
29. Sakata N, Okamura T, Kawa K, et al. Rapid disappearance of AML1/ETO fusion transcript in patients with t(8;21) acute myeloid leukemia following bone marrow transplantation and chemotherapy. Leuk Lymphoma. 1997;26:141-152.
30. Krauter J, Heil G, Ganser A. The AML1/MTG8 Fusion transcript in t(8;21) positive AML and its implication for the detection of minimal residual disease. Hematology. 2001;5:369-381.
31. Trka J, Kalinova M, Stary J, et al. For Czech Paediatric Haematology Working Group. Real-time quantitative PCR detection of WT1 gene expression in children with AML: prognostic significance, correlation with disease status and residual disease detection by flow cytometry. Leukemia. 2002;16:1381-1389.